MAPT and Alzheimer disease: A more recent study in normal patients with AD pathological biomarkers utilized an ePVS visual rating score to suggest that impairment in glymphatic clearance could contribute to tau accumulation through microglia neuroinflammation processes (Zeng et al., 2022).